BRAF and colonic neoplasm: The BEACON trial [18] first demonstrated that both a dual therapy targeting BRAF (encorafenib) and EGFR (cetuximab) and especially a triple combination targeting BRAF (encorafenib), MEK (binimetinib), and EGFR (cetuximab) can increase the survival of colon cancer patients compared to the current standard of care (SoC).